Compare BAND & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | AVXL |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.9M | 397.6M |
| IPO Year | 2017 | N/A |
| Metric | BAND | AVXL |
|---|---|---|
| Price | $14.54 | $5.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $20.67 | ★ $22.00 |
| AVG Volume (30 Days) | 187.1K | ★ 1.8M |
| Earning Date | 02-19-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $756,118,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $15.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.42 | N/A |
| 52 Week Low | $11.33 | $2.86 |
| 52 Week High | $19.88 | $13.99 |
| Indicator | BAND | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.38 | 70.21 |
| Support Level | $13.10 | $4.67 |
| Resistance Level | $14.41 | $5.36 |
| Average True Range (ATR) | 0.52 | 0.32 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 70.59 | 93.29 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.